Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis.
Adolescent
Adult
Aged
Early Detection of Cancer
/ standards
Female
Hematologic Neoplasms
/ epidemiology
Humans
Incidence
Male
Mass Screening
/ standards
Middle Aged
Mycosis Fungoides
/ complications
Neoplasms, Second Primary
/ epidemiology
Practice Guidelines as Topic
Retrospective Studies
Risk Assessment
/ statistics & numerical data
Risk Factors
SEER Program
/ statistics & numerical data
Sex Distribution
Sex Factors
Skin Neoplasms
/ complications
United States
/ epidemiology
Young Adult
CTCL
SEER
Surveillance Epidemiology and End Results
cutaneous T-cell lymphoma
cutaneous lymphoma
mycosis fungoides
non-Hodgkin lymphoma
second malignancy
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
15
02
2019
revised:
11
07
2019
accepted:
24
07
2019
pubmed:
3
8
2019
medline:
24
2
2021
entrez:
3
8
2019
Statut:
ppublish
Résumé
Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized. This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF. We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742). Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF. Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.
Sections du résumé
BACKGROUND
BACKGROUND
Mycosis fungoides (MF) is associated with increased risk of second primary hematologic malignancies, but its association with second primary solid tumors is less well characterized.
OBJECTIVE
OBJECTIVE
This retrospective analysis seeks to assess the risk of being diagnosed with a second primary hematologic or solid malignancy in patients with MF.
DESIGN
METHODS
We performed an analysis of patients diagnosed with MF from 2000 through 2015 in the United States cancer registries of SEER-18 (N = 6742).
RESULTS
RESULTS
Relative risks were estimated by using standardized incidence ratios (SIRs). Among 6742 patients, there were 511 (7.5%) second cancer events (SIR, 10.15; 95% confidence interval [CI], 9.29-11.07). These included 184 (36.0%) hematologic malignancies (SIR, 39.71; 95% CI, 34.05-46.05) and 327 (64.0%) solid tumor malignancies (SIR, 7.33; 95% CI, 6.56-8.17). Patients with MF were at increased risk for non-Hodgkin lymphoma; Hodgkin lymphoma; melanoma; and lung, female breast, prostate, colon, and renal cancers. Females were at higher risk than males (P < .05). All ethnic groups showed a statistically significant elevation in SIRs. Elevation of SIRs was observed across all stages of MF.
CONCLUSIONS AND RELEVANCE
CONCLUSIONS
Patients with MF are at increased risk for diagnosis of second primary malignancies and should be carefully screened for discernable signs and symptoms of second malignancies.
Identifiants
pubmed: 31374302
pii: S0190-9622(19)32466-1
doi: 10.1016/j.jaad.2019.07.075
pmc: PMC7021276
mid: NIHMS1055619
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
404-411Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Informations de copyright
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Références
Cancer. 1989 Apr 15;63(8):1612-5
pubmed: 2924268
Am J Clin Dermatol. 2016 Feb;17(1):71-7
pubmed: 26386881
BMC Cancer. 2014 Apr 18;14:272
pubmed: 24742063
Arch Dermatol. 2007 Jan;143(1):45-50
pubmed: 17224541
JAMA Dermatol. 2014 Jul;150(7):709-15
pubmed: 24718769
J Am Acad Dermatol. 2014 Sep;71(3):529-35
pubmed: 24836079
Clin Diagn Lab Immunol. 1999 Jan;6(1):79-84
pubmed: 9874668
J Clin Invest. 2005 Apr;115(4):798-812
pubmed: 15841167
J Invest Dermatol. 2000 Jul;115(1):62-5
pubmed: 10886509